IN THE CLAIMS:

Claim 1 (original): A quinazoline derivative of the formula I:

$$A \longrightarrow \begin{pmatrix} R^6 \\ R^5 \\ R^{5a} \end{pmatrix} \begin{pmatrix} R^2 \\ R^3 \end{pmatrix}_n \begin{pmatrix} R^3 \\ R^3 \end{pmatrix}_n$$

I

wherein:

m is 0, 1 or 2;

each R¹, which may be the same or different, is selected from hydroxy, (1-6C)alkoxy, (3-7C)cycloalkyl-oxy and (3-7C)cycloalkyl-(1-6C)alkoxy, and wherein any CH₂ or CH₃ group within a R¹ substituent optionally bears on each said CH₂ or CH₃ group one or more halogeno or (1-6C)alkyl substituents, or a substituent selected from hydroxy and (1-6C)alkoxy,

R² is hydrogen or (1-4C)alkyl;

n is 0, 1, 2, 3 or 4;

each R³, which may be the same or different, is selected from cyano, halogeno, (1-4C)alkyl, trifluoromethyl, (1-4C)alkoxy, (2-4C)alkenyl and (2-4C)alkynyl;

 X^1 is selected from O, S, SO, SO₂, N(R⁷), CH(OR⁷), CON(R⁷), N(R⁷)CO, SO₂N(R⁷), N(R⁷)SO₂, OC(R⁷)₂, C(R⁷)₂O, SC(R⁷)₂, C(R⁷)₂S, CO, C(R⁷)₂N(R⁷) and N(R⁷)C(R⁷)₂, wherein each R⁷, which may be the same or different, is hydrogen or (1-6C)alkyl;

Q¹ is aryl, or heteroaryl, and wherein Q¹ optionally bears one or more substituents, which may be the same or different, selected from halogeno, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, sulfamoyl, formyl, mercapto, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl,

(1-6C)alkylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl,

N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl,

(3-6C)alkenoyl, (3-6C)alkynoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino,

 \underline{N} -(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenoylamino, \underline{N} -(1-6C)alkyl-(3-

6C)alkenoylamino, (3-6C)alkynoylamino, N-(1-6C)alkyl-(3-6C)alkynoylamino,

 \underline{N} -(1-6C)alkylsulfamoyl, \underline{N} -di-[(1-6C)alkyl]sulfamoyl, (1-6C)alkanesulfonylamino,

 \underline{N} -(1-6C)alkyl-(1-6C)alkanesulfonylamino, and a group of the formula:

$$-X^{2}-R^{8}$$

wherein X^2 is a direct bond or is selected from O, CO and $N(R^9)$, wherein R^9 is hydrogen or (1-6C)alkyl, and R^8 is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, carboxy-(1-

6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, N-

(1-6C)alkylamino-(1-6C)alkyl, N,N-di-[(1-6C)alkyl]amino-(1-6C)alkyl,

 $(2-6C) alkanoylamino-(1-6C) alkyl, \ \underline{N}-(1-6C) alkyl-(2-6C) alkanoylamino-(1-6C) alkyl,$

(1-6C)alkoxycarbonylamino-(1-6C)alkyl, carbamoyl-(1-6C)alkyl,

 \underline{N} -(1-6C)alkylcarbamoyl-(1-6C)alkyl, \underline{N} -di-[(1-6C)alkyl]carbamoyl-(1-6C)alkyl, (1-6C)alkyl

6C)alkylthio-(1-6C)alkyl, (1-6C)alkylsulfinyl-(1-6C)alkyl, (1-6C)alkylsulfonyl-(1-

6C)alkyl sulfamoyl(1-6C)alkyl, \underline{N} -(1-6C)alkylsulfamoyl(1-6C)alkyl, $\underline{N},\underline{N}$ -

di-(1-6C)alkylsulfamoyl(1-6C)alkyl, (2-6C)alkanoyl-(1-6C)alkyl, (2-6C)alkanoyloxy-(1-6C)alkyl or (1-6C)alkoxycarbonyl-(1-6C)alkyl,

and wherein any CH₂ or CH₃ group within -X¹-Q¹ optionally bears on each said CH₂ or CH₃ group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, cyano, amino, (1-4C)alkoxy, (1-4C)alkylamino and di-[(1-4C)alkylamino];

- R⁴, R^{4a}, R⁵ and R^{5a}, which may be the same or different, are selected from hydrogen and (1-6C)alkyl, or
- R⁴ and R^{4a} together with the carbon atom to which they are attached form a (3-7C)cycloalkyl ring, or
- R⁵ and R^{5a} together with the carbon atom to which they are attached form a (3-7C)cycloalkyl ring,

and wherein any CH₂ or CH₃ group within any of R⁴, R^{4a}, R⁵ and R^{5a} optionally bears on each said CH₂ or CH₃ group one or more halogeno substituents or a substituent selected from hydroxy, cyano, (1-6C)alkoxy, amino, (2-6C)alkanoyl, (1-6C)alkylamino and di-[(1-6C)alkylamino];

R⁶ is selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heterocyclyl and heterocyclyl-(1-6C)alkyl, and wherein any heterocyclyl group within an R⁶ substituent optionally bears one or more substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, formyl, mercapto, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (2-6C)alkanoyl, (2-6C)alkanoyloxy and from a group of the formula:

$$-X^{3}-R^{10}$$

wherein X³ is a direct bond or is selected from O, CO, SO₂ and N(R¹¹), wherein R¹¹ is

hydrogen or (1-4C)alkyl, and R¹⁰ is halogeno-(1-4C)alkyl, hydroxy-(1-4C)alkyl, (1-4C)alkyl, cyano-(1-4C)alkyl, amino-(1-4C)alkyl, <u>N</u>-(1-4C)alkylamino-(1-4C)alkyl and <u>N</u>,<u>N</u>-di-[(1-4C)alkyl]amino-(1-4C)alkyl, and wherein any heterocyclyl group within an R⁶ substituent optionally bears 1 or 2 oxo or thioxo substituents; and wherein any CH₂ or CH₃ group within a R⁶ substituent, other than a CH₂ group within a heterocyclyl group, optionally bears on each said CH₂ or CH₃ group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, cyano, amino, carboxy, carbamoyl, sulfamoyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, <u>N</u>-(1-6C)alkylcarbamoyl, <u>N</u>,<u>N</u>-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkylsulfamoyl. $\underline{N},\underline{N}$ -di-[(1-6C)alkyl]sulfamoyl, (1-6C)alkanesulfonylamino and \underline{N} -(1-6C)alkyl-(1-6C)alkanesulfonylamino;

A is selected from hydrogen, a group of the formula Z- $(CR^{12}R^{13})_p$ - and R^{14} , wherein p is 1, 2, 3, or 4,

- each R¹² and R¹³, which may be the same or different, is selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl and (2-6C)alkynyl,
- or an R¹² and an R¹³ group attached to the same carbon atom form a (3-7C)cycloalkyl or (3-7C)cycloalkenyl ring,
- and wherein any CH₂ or CH₃ group within any of R¹² and R¹³, optionally bears on each said CH₂ or CH₃ group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, cyano, (1-6C)alkyl, (1-6C)alkoxy, amino, (2-6C)alkanoyl, (1-6C)alkylamino and di-[(1-6C)alkyl]amino,
- Z is selected from hydrogen, OR¹⁵, NR¹⁶R¹⁷, (1-6C)alkylsulfonyl,

 (1-6C)alkanesulfonylamino and N-(1-6C)alkyl-(1-6C)alkanesulfonylamino, wherein each of R¹⁵, R¹⁶ and R¹⁷, which may be the same or different, is selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl and (1-6C)alkoxycarbonyl, or Z is a group of the formula:

$$Q^2-X^4-$$

wherein X^4 is selected from O, $N(R^{18})$, SO_2 and $SO_2N(R^{18})$, wherein R^{18} is hydrogen or (1-6C)alkyl, and Q^2 is (3-7C)cycloalkyl, (3-7C)cycloalkenyl or heterocyclyl,

R¹⁴ is selected from hydrogen, OR¹⁹ and NR¹⁶R¹⁷, wherein R¹⁹ is selected from (1-6C)alkyl, (2-6C)alkenyl and (2-6C)alkynyl, and wherein R¹⁶ and R¹⁷ are as defined above,

or R¹⁴ is a group of the formula:

$$Q^3-X^5-$$

wherein X^5 is selected from O and $N(R^{20})$, wherein R^{20} is hydrogen or (1-6C)alkyl, and Q^3 is (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heterocyclyl and heterocyclyl-(1-6C)alkyl,

or R¹⁴ is Q⁴ wherein Q⁴ is (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

- and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a Z or R^{14} substituent are optionally separated by the insertion into the chain of a group selected from O, S, SO, SO₂, N(R^{21}), CO, -C=C- and -C=C-, wherein R^{21} is hydrogen or (1-6C)alkyl,
- and wherein any heterocyclyl group within a Z or R¹⁴ substituent optionally bears one or more substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, formyl, mercapto, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (2-6C)alkanoyl, (2-6C)alkanoyloxy and from a group of the formula:

$$-X^{6}-R^{22}$$

wherein X^6 is a direct bond or is selected from O, CO, SO₂ and N(R²³), wherein R²³ is hydrogen or (1-4C)alkyl, and R²² is halogeno-(1-4C)alkyl, hydroxy-(1-4C)alkyl, (1-4C)alkyl, cyano-(1-4C)alkyl, amino-(1-4C)alkyl,

- <u>N</u>-(1-4C)alkylamino-(1-4C)alkyl and <u>N,N</u>-di-[(1-4C)alkyl]amino-(1-4C)alkyl, and wherein any heterocyclyl group within a Z or R^{14} substituent optionally bears 1 or 2 oxo or thioxo substituents,
- and wherein any CH₂ or CH₃ group within a Z or R¹⁴ group, other than a CH₂ group within a heterocyclyl ring, optionally bears on each said CH₂ or CH₃ group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, cyano, amino, carboxy, carbamoyl, sulfamoyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkylsulfamoyl,

 $\underline{N},\underline{N}$ -di-[(1-6C)alkyl]sulfamoyl, (1-6C)alkanesulfonylamino and \underline{N} -(1-6C)alkyl-(1-6C)alkanesulfonylamino; or a pharmaceutically acceptable salt thereof.

Claim 2 (original): A quinazoline derivative according to claim 1, wherein: m is 0, 1 or 2;

each R¹, which may be the same or different, is selected from hydroxy, (1-6C)alkoxy, (3-7C)cycloalkyl-oxy and (3-7C)cycloalkyl-(1-6C)alkoxy, and wherein any CH₂ or CH₃ group within a R¹ substituent optionally bears on each said CH₂ or CH₃ group one or more halogeno or (1-6C)alkyl substituents, or a substituent selected from hydroxy and (1-6C)alkoxy,

R² is hydrogen or (1-4C)alkyl;

n is 0, 1, 2, 3 or 4;

O¹ is aryl, or heteroaryl,

- each R³, which may be the same or different, is selected from halogeno, (1-4C)alkyl, trifluoromethyl, (1-4C)alkoxy, (2-4C)alkenyl and (2-4C)alkynyl;
- X^1 is selected from O, S, SO, SO₂, N(R⁷), CH(OR⁷), CON(R⁷), N(R⁷)CO, SO₂N(R⁷), N(R⁷)SO₂, OC(R⁷)₂, C(R⁷)₂O, SC(R⁷)₂, C(R⁷)₂S, CO, C(R⁷)₂N(R⁷) and N(R⁷)C(R⁷)₂, wherein each R⁷, which may be the same or different, is hydrogen or (1-6C)alkyl;
 - and wherein Q¹ optionally bears one or more substituents, which may be the same or different, selected from halogeno, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, sulfamoyl, formyl, mercapto, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (3-6C)alkenoyl, (3-6C)alkynoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(3-6C)alkyl-(3-6C)alkynoylamino, (3-6C)alkynoylamino, N-(1-6C)alkyl-(3-6C)alkynoylamino, N-(1-6C)alkyl-(3-6C)alkynoylamino, N-(1-6C)alkyl-(3-6C)alkynoylamino,

 \underline{N} -(1-6C)alkylsulfamoyl, \underline{N} , \underline{N} -di-[(1-6C)alkyl]sulfamoyl, (1-6C)alkanesulfonylamino, \underline{N} -(1-6C)alkyl-(1-6C)alkanesulfonylamino, and a group of the formula:

$$-X^{2}-R^{8}$$

wherein X² is a direct bond or is selected from O, CO and N(R9), wherein R9 is hydrogen or (1-6C)alkyl, and R8 is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, carboxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, N-(1-6C)alkyl, N-(1-6C)alkyl, N-(1-6C)alkyl, N-(1-6C)alkyl, N-(1-6C)alkyl, N-(1-6C)alkyl, N-(1-6C)alkyl, N-(1-6C)alkyl, N-(1-6C)alkyl, Carbamoyl-(1-6C)alkyl, N-(1-6C)alkyl, N-(1-6C)alkyl, N-(1-6C)alkyl, N-(1-6C)alkyl, (1-6C)alkyl, (1-6C)alkyl, (1-6C)alkyl, (1-6C)alkyl, (1-6C)alkyl, N-(1-6C)alkyl, N-(1-6

- and wherein any CH₂ or CH₃ group within -X¹-Q¹ optionally bears on each said CH₂ or CH₃ group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, cyano, amino, (1-4C)alkoxy, (1-4C)alkylamino and di-[(1-4C)alkylamino];
- R⁴, R^{4a}, R⁵ and R^{5a}, which may be the same or different, are selected from hydrogen and (1-6C)alkyl, or
- R⁴ and R^{4a} together with the carbon atom to which they are attached form a (3-7C)cycloalkyl ring, or
- R⁵ and R^{5a} together with the carbon atom to which they are attached form a (3-7C)cycloalkyl ring,
- and wherein any CH₂ or CH₃ group within any of R⁴, R^{4a}, R⁵ and R^{5a} optionally bears on each said CH₂ or CH₃ group one or more halogeno substituents or a substituent selected from hydroxy, cyano, (1-6C)alkoxy, amino, (2-6C)alkanoyl, (1-6C)alkylamino and di-[(1-6C)alkylamino];

R⁶ is selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heterocyclyl and heterocyclyl-(1-6C)alkyl, and wherein any heterocyclyl group within an R⁶ substituent optionally bears one or more substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, formyl, mercapto, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (2-6C)alkanoyl, (2-6C)alkanoyloxy and from a group of the formula:

$$-X^{3}-R^{10}$$

wherein X³ is a direct bond or is selected from O, CO, SO₂ and N(R¹¹), wherein R¹¹ is hydrogen or (1-4C)alkyl, and R¹⁰ is halogeno-(1-4C)alkyl, hydroxy-(1-4C)alkyl, (1-4C)alkoxy-(1-4C)alkyl, cyano-(1-4C)alkyl, amino-(1-4C)alkyl, \underline{N} -(1-4C)alkylamino-(1-4C)alkyl and N,N-di-[(1-4C)alkyl]amino-(1-4C)alkyl, and wherein any heterocyclyl group within an R⁶ substituent optionally bears 1 or 2 oxo or thioxo substituents;

and wherein any CH₂ or CH₃ group within a R⁶ substituent, other than a CH₂ group within a heterocyclyl group, optionally bears on each said CH2 or CH3 group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, cyano, amino, carboxy, carbamoyl, sulfamoyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulfamoyl, N,N-di-[(1-6C)alkyl]sulfamoyl, (1-6C)alkanesulfonylamino and

N-(1-6C)alkyl-(1-6C)alkanesulfonylamino;

A is selected from hydrogen, a group of the formula Z-(CR¹²R¹³)_n- and R¹⁴, wherein p is 1, 2, 3, or 4,

Continuation of Application No.: 10/578,663

each R¹² and R¹³, which may be the same or different, is selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl and (2-6C)alkynyl,

- or an R¹² and an R¹³ group attached to the same carbon atom form a (3-7C)cycloalkyl or (3-7C)cycloalkenyl ring,
- and wherein any CH₂ or CH₃ group within any of R¹² and R¹³, optionally bears on each said CH₂ or CH₃ group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, cyano, (1-6C)alkyl, (1-6C)alkoxy, amino, (2-6C)alkanoyl, (1-6C)alkylamino and di-[(1-6C)alkyl]amino,
- Z is selected from hydrogen, OR¹⁵, NR¹⁶R¹⁷, (1-6C)alkylsulfonyl, (1-6C)alkanesulfonylamino and N-(1-6C)alkyl-(1-6C)alkanesulfonylamino, wherein each of R¹⁵, R¹⁶ and R¹⁷, which may be the same or different, is selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl and (2-6C)alkynyl,

or Z is a group of the formula:

$$Q^2-X^4$$

wherein X⁴ is selected from O, N(R¹⁸), SO₂ and SO₂N(R¹⁸), wherein R¹⁸ is hydrogen or (1-6C)alkyl, and Q² is (3-7C)cycloalkyl, (3-7C)cycloalkenyl or heterocyclyl, R¹⁴ is selected from hydrogen, OR¹⁹ and NR¹⁶R¹⁷, wherein R¹⁹ is selected from (1-

6C)alkyl, (2-6C)alkenyl and (2-6C)alkynyl, and wherein R¹⁶ and R¹⁷ are as defined above,

or R¹⁴ is a group of the formula:

$$Q^3-X^5-$$

wherein X^5 is selected from O and $N(R^{20})$, wherein R^{20} is hydrogen or (1-6C)alkyl. and Q³ is (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heterocyclyl and heterocyclyl-(1-6C)alkyl, or R¹⁴ is Q⁴ wherein Q⁴ is (3-7C)cycloalkyl, (3-7C)cycloalkenyl or heterocyclyl, and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a Z or R¹⁴ substituent are optionally separated by the insertion into the chain of a group selected from O, S, SO, SO₂, N(R²¹), CO, -C=C- and -C=C-, wherein R²¹ is hydrogen or (1-6C)alkyl,

ATTORNEY DOCKET NO.: 056291-5283

Continuation of Application No.: 10/578,663

Page 11

and wherein any heterocyclyl group within a Z or R¹⁴ substituent optionally bears one or more substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, formyl, mercapto, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (2-6C)alkanoyl, (2-6C)alkanoyloxy and from a group of the formula:

$$-X^{6}-R^{22}$$

wherein X^6 is a direct bond or is selected from O, CO, SO₂ and N(R²³), wherein R²³ is hydrogen or (1-4C)alkyl, and R²² is halogeno-(1-4C)alkyl, hydroxy-(1-4C)alkyl, (1-4C)alkyl, cyano-(1-4C)alkyl, amino-(1-4C)alkyl,

 \underline{N} -(1-4C)alkylamino-(1-4C)alkyl and $\underline{N},\underline{N}$ -di-[(1-4C)alkyl]amino-(1-4C)alkyl, and wherein any heterocyclyl group within a Z or R^{14} substituent optionally bears 1 or 2 oxo or thioxo substituents,

and wherein any CH₂ or CH₃ group within a Z or R¹⁴ group, other than a CH₂ group within a heterocyclyl ring, optionally bears on each said CH₂ or CH₃ group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, cyano, amino, carboxy, carbamoyl, sulfamoyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, N-(1-6C)alkylcarbamoyl, NN-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulfamoyl, NN-di-[(1-6C)alkyl]sulfamoyl, (1-6C)alkanosulfonylamino and N-(1-6C)alkyl-(1-6C)alkanosulfonylamino;

or a pharmaceutically acceptable salt thereof.

Claim 3 (**currently amended**): A quinazoline derivative according to claim 1-or-claim 2, wherein R⁴, R^{4a}, R⁵ and R^{5a}, which may be the same or different, are selected from hydrogen and (1-6C)alkyl, and wherein any CH₂ or CH₃ group within any of R⁴, R^{4a}, R⁵ and R^{5a} optionally bears on each said CH₂ or CH₃ group one or more halogeno substituents or a substituent selected

from hydroxy, cyano, (1-6C)alkoxy, amino, (2-6C)alkanoyl, (1-6C)alkylamino and di-[(1-6C)alkylamino and di-[(1-6C)alkylam 6C)alkylamino].

Claim 4 (currently amended): A quinazoline derivative according to claim 1 any one of the preceding claims, wherein m is 0.

Claim 5 (currently amended): A quinazoline derivative according to claim 1 any one of the preceding claims, wherein R² is hydrogen.

Claim 6 (currently amended): A quinazoline derivative according to claim 1-any one of the preceding claims, wherein n is 0, 1 or 2 and, when present, at least one R³ is in a metaposition (3-position) relative to the nitrogen of the anilino group in formula I.

Claim 7 (currently amended): A quinazoline derivative according to claim 1 any one of the preceding claims, wherein n is 1 and R³ is selected from halogeno and (1-4C)alkyl.

Claim 8 (original): A quinazoline derivative according to claim 7, wherein R³ is chloro.

Claim 9 (original): A quinazoline derivative according to claim 7, wherein R³ is methyl.

Claim 10 (currently amended): A quinazoline derivative according to claim 1 any one of the preceding claims, wherein X¹ is selected from O, S, OC(R⁷)₂, SC(R⁷)₂, SO, SO₂, N(R⁷), CO and N(R⁷)C(R⁷)₂ wherein each R⁷, which may be the same or different, is selected from hydrogen or (1-6C)alkyl.

Claim 11 (currently amended): A quinazoline derivative according to claim 1-any-one of the preceding claims, wherein X^1 is selected from O, S and $OC(R^7)_2$ wherein each R^7 is, independently, hydrogen or (1-4C)alkyl.

Claim 12 (currently amended): A quinazoline derivative according to claim 1 any one of the preceding claims, wherein X^1 is OCH₂.

Claim 13 (currently amended): A quinazoline derivative according to <u>claim 1</u> any one of the preceding claims, wherein Q¹ is selected from phenyl and a 5- or 6-membered monocyclic heteroaryl ring, which ring contains 1, 2 or 3 heteroatoms independently selected from oxygen, nitrogen and sulfur,

and wherein Q¹ optionally bears one or more substituents, which may be the same or different, selected from halogeno, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, sulfamoyl, formyl, mercapto, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (3-6C)alkenoyl, (3-6C)alkynoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkenoylamino, N-(1-6C)alkyl-(3-6C)alkylsulfamoyl, N,N-di-[(1-6C)alkyl]sulfamoyl, (1-6C)alkynoylamino, N-(1-6C)alkyl-(1-

$$-X^{2}-R^{8}$$

wherein X^2 is a direct bond or is selected from O, CO and N(R⁹), wherein R⁹ is hydrogen or (1-6C)alkyl, and R⁸ is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, carboxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, N-(1-6C)alkyl, N-di-[(1-6C)alkyl]amino-(1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl, N-(1-6C)alkyl-(2-6C)alkanoylamino-(1-6C)alkyl, (1-6C)alkoxycarbonylamino-(1-6C)alkyl, carbamoyl-(1-6C)alkyl, N-(1-6C)alkyl, N-(1-6C)alkyl, N-(1-6C)alkyl, (1-6C)alkyl) [(1-6C)alkyl, (1-6C)alkyl, (1-6C)alkyl, (1-6C)alkyl, (1-6C)alkyl, N-(1-6C)alkyl, N-(1-6

di-(1-6C)alkylsulfamoyl(1-6C)alkyl, (2-6C)alkanoyl-(1-6C)alkyl, (2-6C)alkanoyloxy-(1-6C)alkyl or (1-6C)alkoxycarbonyl-(1-6C)alkyl,

and wherein any CH₂ or CH₃ group within -X¹-Q¹ optionally bears on each said CH₂ or CH₃ group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, cyano, amino, (1-4C)alkoxy, (1-4C)alkylamino and di-[(1-4C)alkylamino].

Claim 14 (**currently amended**): A quinazoline derivative according to <u>claim 1</u> any one of the preceding claims, wherein Q¹ is selected from phenyl, pyridyl, pyrazinyl, 1,3-thiazolyl, 1H-imidazolyl, 1H-pyrazolyl, 1,3-oxazolyl and isoxazolyl.

Claim 15 (**currently amended**): A quinazoline derivative according to <u>claim 1</u> any one of the preceding claims, wherein R⁶ is selected from hydrogen, (1-3C)alkyl, (2-3C)alkenyl, (2-3C)alkynyl, (3-5C)cycloalkyl-(1-3C)alkyl, heterocyclyl and heterocyclyl-(1-3C)alkyl,

wherein any heterocyclyl group within R⁶ is a 4, 5, 6 or 7 membered monocyclic saturated or partially saturated heterocyclyl ring containing 1 or 2 heteroatoms selected from oxygen, nitrogen and sulfur, which heterocyclyl group is linked to the group to which it is attached by a ring carbon atom,

and wherein any heterocyclyl group within an R⁶ substituent optionally bears one or more substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, mercapto, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (2-6C)alkanoyl, (2-6C)alkanoyloxy and from a group of the formula:

$$-X^{3}-R^{10}$$

wherein X^3 is a direct bond or is selected from O and N(R¹¹), wherein R¹¹ is hydrogen or (1-4C)alkyl, and R¹⁰ is halogeno-(1-4C)alkyl, hydroxy-(1-4C)alkyl, (1-4C)alkyl, cyano-(1-4C)alkyl, amino-(1-4C)alkyl, N-(1-4C)alkylamino-(1-4C)alkyl and N-(1-4C)alkylamino-(1-4C)alkyl,

and wherein any heterocyclyl group within an R⁶ substituent optionally bears 1 or 2 oxo substituents;

and wherein any CH₂ or CH₃ group within a R⁶ substituent, other than a CH₂ group within a heterocyclyl group, optionally bears on each said CH₂ or CH₃ group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, amino, (1-6C)alkoxy, (1-6C)alkylamino and di-[(1-6C)alkyl]amino.

Claim 16 (original): A quinazoline derivative according to claim 15, wherein R⁶ is (1-3C)alkyl,

and wherein any CH₂ or CH₃ group within a R⁶ substituent, other than a CH₂ group within a heterocyclyl group, optionally bears on each said CH₂ or CH₃ group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, amino, (1-6C)alkoxy, (1-6C)alkylamino and di-[(1-6C)alkyl]amino.

Claim 17 (currently amended): A quinazoline derivative according to claim 1 any one of the preceding claims, wherein A is selected from a group of the formula $Z-(CR^{12}R^{13})_p$ and R^{14} ,

wherein p is 1, 2 or 3,

- each R¹² and R¹³, which may be the same or different, is selected from hydrogen and (1-6C)alkyl,
- and wherein any CH₂ or CH₃ group within any of R¹² and R¹³ optionally bears on each said CH₂ or CH₃ group one or more halogeno substituents or a substituent selected from hydroxy and (1-6C)alkoxy,
- Z is selected from hydrogen, OR¹⁵, NR¹⁶R¹⁷ and (1-6C)alkylsulfonyl, wherein each of R¹⁵, R¹⁶ and R¹⁷, which may be the same or different, is selected from hydrogen, (1-6C)alkyl and (1-6C)alkoxycarbonyl,
- R¹⁴ is selected from OR¹⁹ and NR¹⁶R¹⁷, wherein R¹⁹ is selected from (1-6C)alkyl and wherein R¹⁶ and R¹⁷ are as defined above,
- or R¹⁴ is Q⁴ wherein Q⁴ is (3-7C)cycloalkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

- and wherein any heterocyclyl group within a Z or R¹⁴ substituent optionally bears one or more substituents, which may be the same or different, selected from halogeno, hydroxy, (1-6C)alkyl and (1-6C)alkoxy,
- and wherein any CH₂ or CH₃ group within a Z or R¹⁴ group, other than a CH₂ group within a heterocyclyl ring, optionally bears on each said CH₂ or CH₃ group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy and (1-6C)alkoxy.
- Claim 18 (**original**): A quinazoline derivative selected from one or more of the following:
- *N*-{2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy]ethyl}-2-methoxy-*N*-methylacetamide;
- *N*-{2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy]ethyl}-2-(dimethylamino)-*N*-methylacetamide;
- *N*-{(2*R*)-2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy]propyl}-2-methoxy-*N*-methylacetamide);
- 2-hydroxy-*N*-methyl-*N*-{2-[(4-{3-methyl-4-(pyrazin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy]ethyl}acetamide;
- 2-hydroxy-*N*-methyl-*N*-{2-[(4-{3-methyl-4-(1,3-thiazol-4-ylmethoxy)anilino}quinazolin-5-yl)oxy]ethyl}acetamide;
- 2-hydroxy-*N*-methyl-*N*-(2-{[4-(3-methyl-4-[(5-methylisoxazol-3-yl)methoxy]anilino)quinazolin-5-yl]oxy}ethyl)acetamide;
- *N*-{(2*R*)-2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy]propyl}-2-methoxyacetamide;
- *N*-(2-{[4-(3-chloro-4-[(6-methylpyridin-2-yl)methoxy]anilino)quinazolin-5-yl]oxy}ethyl)-2-hydroxy-*N*-methylacetamide;
- *N*-((2*R*)-2-{[4-(3-chloro-4-[(6-methylpyridin-2-yl)methoxy]anilino)quinazolin-5-yl]oxy}propyl)-2-hydroxy-*N*-methylacetamide;
- *N*-(2-{[4-(3-chloro-4-[(6-methylpyridin-2-yl)methoxy]anilino)quinazolin-5-yl]oxy}ethyl)-*N*-methylacetamide;

- N-(2-{[4-(3-chloro-4-[(2-fluorobenzyl)oxy]anilino)quinazolin-5-yl]oxy}ethyl)-Nmethylacetamide;
- $N-(2-\{[4-(3-\text{chloro}-4-[(3-\text{fluorobenzyl})\text{oxy}]\text{anilino})\text{quinazolin-5-yl}]\text{oxy}\}\text{ ethyl})-N$ methylacetamide;
- N-{2-[(4-{3-chloro-4-(1,3-thiazol-4-ylmethoxy)anilino}quinazolin-5-yl)oxy]ethyl}-Nmethylacetamide;
- N-{2-[(4-{3-chloro-4-(pyrazin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy]ethyl}-Nmethylacetamide;
- N-{(2R)-2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy|propyl}-2hydroxyacetamide;
- N-{2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy]ethyl}-Nmethylacetamide;
- 2-hydroxy-N-methyl-N-{2-[(4-{3-methyl-4-(pyridin-2-ylmethoxy)anilino}quinazolin-5yl)oxy]ethyl}acetamide;
- $N-\{(1R)-2-[(4-\{3-\text{chloro-}4-(\text{pyridin-}2-\text{ylmethoxy})\text{anilino}\}\text{quinazolin-}5-\text{yl})\text{oxy}]-1$ methylethyl}acetamide;
- $N-\{(1R)-2-[(4-\{3-\text{chloro}-4-(\text{pyridin}-2-\text{ylmethoxy})\text{anilino}\}\text{ quinazolin}-5-\text{yl})\text{ oxy}]-1-\text{methylethyl}\}$ 2-hydroxyacetamide;
- N-{2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy]ethyl}-2-hydroxy-Nmethylacetamide;
- $N-(2-\{[4-(3-\text{chloro}-4-[(3-\text{fluorobenzyl})\text{oxy}]\text{anilino})\text{quinazolin-5-yl}]\text{oxy}\}\text{ ethyl})-2-\text{hydroxy-}N$ methylacetamide;
- N-{2-[(4-{3-chloro-4-(1,3-thiazol-4-ylmethoxy)anilino}quinazolin-5-yl)oxy]ethyl}-2-hydroxy-*N*-methylacetamide;
- $N-\{2-[(4-\{3-\text{chloro-}4-(\text{pyrazin-}2-\text{ylmethoxy})\text{anilino}\}\text{quinazolin-}5-\text{yl})\text{oxy}]\text{ethyl}\}-2-\text{hydroxy-}N$ methylacetamide;
- N-{2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy]ethyl}acetamide;
- $N-\{(2R)-2-[(4-\{3-\text{chloro-}4-(\text{pyridin-}2-\text{ylmethoxy})\text{anilino}\}\text{quinazolin-}5-\text{yl})\text{oxy}]\text{propyl}\}$ acetamide;

- *N*-{(2*R*)-2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy]propyl}-2-hydroxy-*N*-methylacetamide;
- *N*-{(2*R*)-2-[(4-{3-chloro-4-(pyrazin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy]propyl}-2-hydroxy-*N*-methylacetamide;
- *N*-((2*R*)-2-{[4-(3-chloro-4-[(3-fluorobenzyl)oxy]anilino)quinazolin-5-yl]oxy}propyl)-2-hydroxy-*N*-methylacetamide;
- $N-\{(2R)-2-[(4-\{3-\text{chloro-}4-(1,3-\text{thiazol-}4-\text{ylmethoxy})\text{anilino}\}\text{quinazolin-}5-\text{yl})\text{oxy}]\text{propyl}\}-2-\text{hydroxy-}N-\text{methylacetamide};$
- *N*-{(2*R*)-2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy]propyl}-*N*-methylacetamide;
- *N*-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-*N*-ethylacetamide;
- *N*-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-*N*-ethyl-2-hydroxyacetamide;
- *N*-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-*N*-propylacetamide;
- *N*-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-2-hydroxy-*N*-propylacetamide;
- *N*-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-*N*-isopropylacetamide;
- *N*-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-2-hydroxy-*N*-isopropylacetamide;
- *N*-allyl-*N*-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl} acetamide;
- *N*-allyl-*N*-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-2-hydroxyacetamide;
- *N*-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-*N*-cyclopropylacetamide;

Continuation of Application No.: 10/578,663

- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-Ncyclopropyl-2-hydroxyacetamide;
- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-N-(cyclopropylmethyl)acetamide;
- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-N-(cyclopropylmethyl)-2-hydroxyacetamide;
- $N-\{2-[(4-\{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino\}quinazolin-5-yl)oxy]ethyl\}-N$ cyclobutylacetamide;
- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-Ncyclobutyl-2-hydroxyacetamide;
- $N-\{2-[(4-\{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino\}quinazolin-5-yl)oxy]ethyl\}-N-(1-ylmethoxy)phenyl]amino\}quinazolin-5-yloxy]ethyl}-N-(1-ylmethoxy)phenyl]amino}quinazolin-5-yloxy]ethyl$ methylpiperidin-4-yl)acetamide;
- $N-\{2-[(4-\{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino\}quinazolin-5-yl)oxy]ethyl\}-N-$ (tetrahydro-2*H*-pyran-4-yl)acetamide;
- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-2hydroxy-*N*-(tetrahydro-2*H*-pyran-4-yl)acetamide;
- $N-\{2-[(4-\{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino\}quinazolin-5-yl)oxy]ethyl\}-N-(2-ylmethoxy)phenyl]amino\}quinazolin-5-yloxy]ethyl}-N-(2-ylmethoxy)phenyl]amino}quinazolin-5-yloxy]ethyl$ hydroxyethyl)acetamide;
- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-2hydroxy-N-(2-hydroxyethyl)acetamide;
- $N-\{2-[(4-\{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino\}quinazolin-5-yl)oxy]ethyl\}-N-(2-ylmethoxy)phenyl]amino\}quinazolin-5-yl)oxy]ethyl}-N-(2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-N-(2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-N-(2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-N-(2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-N-(2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-N-(2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl$ methoxyethyl)acetamide;
- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-2hydroxy-N-(2-methoxyethyl)acetamide;
- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-N-prop-2-yn-1-ylacetamide;
- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-2hydroxy-N-prop-2-yn-1-ylacetamide;

- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-2hydroxy-*N*-methylpropanamide;
- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-Nmethyl-tetrahydrofuranyl-2-carboxamide;
- $N-\{2-[(4-\{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino\}guinazolin-5-yl)oxy]ethyl\}-N,1$ dimethylprolinamide;
- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-2hydroxy-N,2-dimethylpropanamide;
- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-1hydroxy-N-methylcyclopropanecarboxamide;
- N^{1} -{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}- N^{1} , N^{2} dimethylglycinamide;
- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-3hydroxy-*N*,2,2-trimethylpropanamide;
- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-3hydroxy-N-methylpropanamide;
- $N-\{(2S)-2-[(4-\{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino\}]$ quinazolin-5yl)oxy|propyl}acetamide;
- $N-\{(2S)-2-[(4-\{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino\}quinazolin-5-yl)oxy]propyl\}-2$ hydroxyacetamide;
- N^{1} -{(2S)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}- N^2 , N^2 -dimethylglycinamide;
- $N-\{(2S)-2-[(4-\{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino\}quinazolin-5-yl)oxy]propyl\}-2$ methoxyacetamide;
- $N-\{(2S)-2-[(4-\{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino\}guinazolin-5-yl)oxylpropyl\}-2-$ (methylsulfonyl)acetamide;
- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-2hydroxyacetamide;

- N^{1} -{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}- N^{2} - N^{2} dimethylglycinamide;
- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-2methoxyacetamide;
- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxylethyl}-2-(methylsulfonyl)acetamide;
- $N-\{(2S)-2-[(4-\{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino\}quinazolin-5-yl)oxy[propyl]-N$ methylacetamide;
- $N-\{(2S)-2-[(4-\{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino\}quinazolin-5-yl)oxy[propyl]-2$ hydroxy-N-methylacetamide;
- N^{1} -{(2S)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}- N^1, N^2, N^2 -trimethylglycinamide;
- $N-\{(2S)-2-[(4-\{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino\}]$ quinazolin-5-yl)oxy[propyl]-2methoxy-N-methylacetamide;
- $N-\{(2S)-2-[(4-\{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino\}quinazolin-5-yl)oxy[propyl]-N$ methyl-2-(methylsulfonyl)acetamide;
- $N-\{(2R)-2-[(4-\{[3-chloro-4-(pyrazin-2-ylmethoxy)phenyl]amino\}guinazolin-5-yl)oxy]propyl\}$ *N*-methylacetamide;
- $N-\{(2R)-2-[(4-\{[3-chloro-4-(1,3-thiazol-4-ylmethoxy)phenyl]amino\}quinazolin-5$ yl)oxy[propyl]-N-methylacetamide;
- $N-((2R)-2-\{[4-(\{3-\text{chloro}-4-[(3-\text{fluorobenzyl})\text{oxy}]\text{phenyl}\}\text{amino}\}\text{quinazolin-5-yl}]\text{oxy}\text{propyl}-N$ methylacetamide;
- $N-((2R)-2-\{[4-(\{3-\text{chloro-}4-[(2-\text{fluorobenzyl})\text{oxy}]\text{phenyl}\}\text{amino})\text{quinazolin-}5-yl]\text{oxy}\text{propyl})-N$ methylacetamide:
- $N-\{(1R)-2-[(4-\{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino\}quinazolin-5-yl)oxy]-1$ methylethyl}-2-hydroxy-N-methylacetamide;
- $N-\{(1R)-2-[(4-\{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino\}quinazolin-5-yl)oxy]-1$ methylethyl}-N-methylacetamide;

- *N*-{(1*S*)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]-1-methylethyl}-2-hydroxy-*N*-methylacetamide;
- *N*-{(1*S*)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]-1-methylethyl}-*N*-methylacetamide;
- N-{(1S)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]-1-methylethyl}-2-methoxy-N-methylacetamide;
- *N*-{(1*S*)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]-1-methylethyl}-2-hydroxyacetamide;
- *N*-{(1*S*)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]-1-methylethyl}acetamide;
- N^{1} -{(1S)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]-1-methylethyl}- N^{2} , N^{2} -dimethylglycinamide;
- N^{1} -{(2R)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}- N^{2} , N^{2} -dimethylglycinamide;
- (2*S*)-*N*-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-2,4-dihydroxybutanamide;
- (2*R*)-*N*-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-2,4-dihydroxybutanamide;
- (2R)-N-{(2R)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}-2,4-dihydroxybutanamide;
- (2S)-N-{(2R)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}-2,4-dihydroxybutanamide;
- (2*R*)-*N*-{(2*S*)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}-2,4-dihydroxybutanamide;
- (2S)-N-{(2S)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}-2,4-dihydroxybutanamide;
- (2S)-N-{(1R)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]-1-methylethyl}-2,4-dihydroxybutanamide;

- (2*R*)-*N*-{(1*R*)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]-1-methylethyl}-2,4-dihydroxybutanamide;
- (2*R*)-*N*-{2-[(4-{[3-chloro-4-(1,3-thiazol-4-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-2,4-dihydroxybutanamide;
- (2S)-N-{2-[(4-{[3-chloro-4-(1,3-thiazol-4-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-2,4-dihydroxybutanamide;
- (2*R*)-*N*-{(1*R*)-2-[(4-{[3-chloro-4-(1,3-thiazol-4-ylmethoxy)phenyl]amino} quinazolin-5-yl)oxy]-1-methylethyl}-2,4-dihydroxybutanamide;
- (2*S*)-*N*-{(1*R*)-2-[(4-{[3-chloro-4-(1,3-thiazol-4-ylmethoxy)phenyl]amino} quinazolin-5-yl)oxy]-1-methylethyl}-2,4-dihydroxybutanamide;
- *N*-methyl-*N*-{2-[(4-{[3-methyl-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl} acetamide;
- *N*-methyl-*N*-{2-[(4-{[3-methyl-4-(1,3-thiazol-4-ylmethoxy)phenyl]amino} quinazolin-5-yl)oxy]ethyl} acetamide;
- *N*-methyl-*N*-(2-{[4-({3-methyl-4-[(5-methylisoxazol-3-yl)methoxy]phenyl}amino) quinazolin-5-yl]oxy}ethyl)acetamide;
- 2-hydroxy-*N*-methyl-*N*-{2-[(4-{[3-methyl-4-(1,3-thiazol-2-ylmethoxy)phenyl] amino}quinazolin-5-yl)oxy]ethyl} acetamide;
- 2-hydroxy-*N*-{2-[(4-{[3-methyl-4-(pyridin-2-ylmethoxy)phenyl]amino} quinazolin-5-yl)oxy]ethyl}acetamide;
- 2-hydroxy-*N*-{2-[(4-{[3-methyl-4-(1,3-thiazol-4-ylmethoxy)phenyl]amino} quinazolin-5-yl)oxy]ethyl} acetamide;
- *N*-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]-1,1-dimethylethyl}-2-hydroxyacetamide;
- 2-hydroxy-*N*-{(2*R*)-2-[(4-{[3-methyl-4-(pyridin-2-ylmethoxy)phenyl]amino} quinazolin-5-yl)oxy]propyl}acetamide;
- 2-hydroxy-N-{(2R)-2-[(4-{[3-methyl-4-(1,3-thiazol-4-ylmethoxy)phenyl]amino} quinazolin-5-yl)oxy[propyl}acetamide;

- *N*-((2*R*)-2-{[4-({4-[(3-fluorobenzyl)oxy]-3-methylphenyl}amino)quinazolin-5-yl]oxy}propyl)-2-hydroxyacetamide;
- 2-hydroxy-*N*-{(2*R*)-2-[(4-{[3-methyl-4-(1,3-thiazol-2-ylmethoxy)phenyl]amino} quinazolin-5-yl)oxy]propyl}acetamide;
- *N*-{(2*R*)-2-[(4-{[3-methyl-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}acetamide;
- N-{(2R)-2-[(4-{[3-methyl-4-(1,3-thiazol-4-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}acetamide;
- $N-((2R)-2-\{[4-(\{4-[(3-fluorobenzyl)oxy]-3-methylphenyl\}amino)quinazolin-5-yl]oxy\}$ propyl)acetamide;
- N-{(2R)-2-[(4-{[3-methyl-4-(1,3-thiazol-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}acetamide;
- 2-hydroxy-*N*-methyl-*N*-{(2*R*)-2-[(4-{[3-methyl-4-(pyridin-2-ylmethoxy)phenyl] amino}quinazolin-5-yl)oxy|propyl}acetamide;
- 2-hydroxy-*N*-methyl-*N*-{(2*R*)-2-[(4-{[3-methyl-4-(1,3-thiazol-4-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}acetamide;
- 2-hydroxy-*N*-methyl-*N*-((2*R*)-2-{[4-({3-methyl-4-[(5-methylisoxazol-3-yl)methoxy]phenyl}amino)quinazolin-5-yl]oxy}propyl)acetamide;
- *N*-methyl-*N*-{(1*R*)-1-methyl-2-[(4-{[3-methyl-4-(pyridin-2-ylmethoxy)phenyl] amino}quinazolin-5-yl)oxy]ethyl} acetamide;
- N-methyl-N-{(1R)-1-methyl-2-[(4-{[3-methyl-4-(1,3-thiazol-4-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}acetamide;
- *N*-{(1*R*)-2-[(4-{[3-chloro-4-(1,3-thiazol-4-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]-1-methylethyl}-2-hydroxy-*N*-methylacetamide;
- 2-hydroxy-*N*-methyl-*N*-{(1*R*)-1-methyl-2-[(4-{[3-methyl-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}acetamide;
- 2-hydroxy-*N*-methyl-*N*-{(1*R*)-1-methyl-2-[(4-{[3-methyl-4-(1,3-thiazol-4-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}acetamide;

- *N*-{(2*R*)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}-1-hydroxy-*N*-methylcyclopropanecarboxamide;
- (2S)-N-{(2R)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}-2-hydroxy-N-methylpropanamide;
- N-{(2R)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}-2-hydroxy-N,2-dimethylpropanamide;
- (2*R*)-*N*-{(2*R*)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}-2-hydroxy-*N*-methylpropanamide;
- (2*R*)-*N*-{(2*R*)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}-2-methoxy-*N*-methylpropanamide;
- 2-hydroxy-*N*-methyl-*N*-((2*R*)-2-{[4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)quinazolin-5-yl]oxy}propyl)acetamide;
- N-methyl-N-((2R)-2-{[4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)quinazolin-5-yl]oxy}propyl)acetamide;
- N^1, N^2, N^2 -trimethyl- N^1 -((2R)-2-{[4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)quinazolin-5-yl]oxy}propyl)glycinamide;
- *N*-methyl-*N*-((2*R*)-2-{[4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)quinazolin-5-yl]oxy}propyl)-2-pyrrolidin-1-ylacetamide;
- *N*-methyl-*N*-((2*R*)-2-{[4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)quinazolin-5-yl]oxy}propyl)-2-morpholin-4-ylacetamide;
- N-methyl-N-((2R)-2-{[4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)quinazolin-5-yl]oxy}propyl)-2-(4-methylpiperazin-1-yl)acetamide;
- 2-hydroxy-*N*-methyl-*N*-((2*S*)-2-{[4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)quinazolin-5-yl]oxy}propyl)acetamide;
- N-methyl-N-((2S)-2-{[4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)quinazolin-5-yl]oxy}propyl)acetamide;
- N-methyl-N-((2S)-2-{[4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)quinazolin-5-yl]oxy}propyl)-2-pyrrolidin-1-ylacetamide;

- (2S)-2,4-dihydroxy-N-((2R)-2- $\{[4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy}phenyl\}amino)quinazolin-5-yl]oxy}propyl)butanamide;$
- (2*S*)-4-bromo-2-hydroxy-*N*-((2*R*)-2-{[4-($\{3\text{-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)quinazolin-5-yl]oxy}propyl)butanamide;$
- N-(2-chloroethyl)-N-((2R)-2-{[4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)quinazolin-5-yl]oxy}propyl)urea;
- 2-hydroxy-N-methyl-N-((1R)-1-methyl-2-{[4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)quinazolin-5-yl]oxy}ethyl)acetamide;
- N-methyl-N-((1R)-1-methyl-2-{[4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)quinazolin-5-yl]oxy}ethyl)acetamide;
- 2-hydroxy-*N*-methyl-*N*-((1*S*)-1-methyl-2-{[4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)quinazolin-5-yl]oxy}ethyl)acetamide;
- N-methyl-N-((1S)-1-methyl-2-{[4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)quinazolin-5-yl]oxy}ethyl)acetamide;
- methyl-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}methylcarbamate;
- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-N,N-dimethylurea;
- N'-(2-chloroethyl)-N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-N-methylurea;
- $N-\{(2R)-2-[(4-\{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino\}quinazolin-5-yl)oxy]propyl\}-N'-methylurea;$
- [((R)-2-{4-[3-chloro-4-(pyridin-2-ylmethoxy)phenylamino]quinazolin-5-yloxy}propylcarbamoyl)methyl]methylcarbamic acid <u>tert</u>-butyl ester;
- N^{1} -{(2R)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}- N^{2} -methylglycinamide;
- 2-hydroxy-*N*-methyl-*N*-(2-{[4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)quinazolin-5-yl]oxy}ethyl)acetamide;

N-methyl-N-(2-{[4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)quinazolin-5-yl]oxy}ethyl)acetamide; and

N-{2-[(4-{[3-chloro-4-(1-methyl-1-pyridin-2-ylethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-N-methylacetamide;

or a pharmaceutically acceptable salt thereof.

Claim 19 (currently amended): A pharmaceutical composition which comprises a quinazoline derivative of the formula I, or a pharmaceutically acceptable salt thereof, as defined in claim 1 or claim 18 any one of claims 1 to 18 in association with a pharmaceutically-acceptable diluent or carrier.

Claims 20-23 (cancelled).

Claim 24 (**currently amended**): A process for the preparation of a quinazoline derivative of the formula I, or a pharmaceutically acceptable salt thereof, as defined in claim 1 which comprises:

<u>a)</u> the coupling, <u>optionally conveniently</u> in the presence of a suitable base, of a quinazoline of the formula **II**:

$$\begin{array}{c|c}
R^{6} & R^{5} & R^{4} \\
R^{5a} & R^{2} & R^{2} \\
R^{5a} & R^{3} & R^{2} \\
R^{1} & R^{3} & R^{2} \\
R^{1} & R^{3} & R^{3} & R^{3}
\end{array}$$

 \mathbf{II}

wherein R¹, R², R³, R⁴, R^{4a}, R⁵, R^{5a}, R⁶, X¹, Q¹, m, and n have any of the meanings defined in claim 1 except that any functional group is <u>optionally</u> protected <u>if necessary</u>, with a carboxylic acid of the formula **III**, or a reactive derivative thereof:

A-COOH

Ш

wherein A has any of the meanings defined in claim 1 except that any functional group is optionally protected if necessary;

or

(b) for the preparation of those compounds of the formula I wherein X^1 is $OC(R^7)_2$, $SC(R^7)_2$ or $N(R^7)C(R^7)_2$, the reaction, conveniently in the presence of a suitable base, of a quinazoline of the formula IV:

$$A \xrightarrow{R^6} R^5 \xrightarrow{R^4} R^2 \xrightarrow{N} (R^3)_n$$

$$(R^1)_m$$

IV

wherein X^{1a} is O, S or $N(R^7)$ and R^1 , R^2 , R^3 , R^4 , R^{4a} , R^5 , R^{5a} , R^6 , R^7 , A, m, and n have any of the meanings defined in claim 1 except that any functional group is <u>optionally</u> protected <u>if necessary</u>, with a compound of the formula V or a salt thereof:

$$Q^1-C(R^7)_2-L^1$$

V

wherein L¹ is a suitable displaceable group and Q¹ and R⁷ have any of the meanings defined in claim 1 except that any functional group is <u>optionally</u> protected <u>if necessary</u>;

(c) for the preparation of those compounds of the formula I wherein A is R¹⁴ and R¹⁴ is NHR¹⁷ or Q³-X⁵- (wherein R¹⁷ and Q³ are as defined in claim 1 and X⁵ is NH), the coupling of a quinazoline of the formula II as defined above in (a) with an isocyanate of the formula IIIa:

A-NCO

IIIa

wherein A is R¹⁴ as previously defined in this section except that any functional group is optionally protected if necessary;

(d) the reaction of a quinazoline of the formula II wherein R⁶ is hydrogen:

$$H \xrightarrow{R^5} R^4$$

$$R^{2}$$

$$R^{5a}$$

$$R^{5a}$$

$$R^{1}$$

$$R^{1}$$

$$R^{1}$$

$$R^{1}$$

$$R^{2}$$

$$R^{2}$$

$$R^{3}$$

$$R^{3}$$

$$R^{3}$$

II

wherein R^1 , R^2 , R^3 , R^4 , R^{4a} , R^5 , R^{5a} , X^1 , Q^1 , m, and n have any of the meanings defined in claim 1 except that any functional group is <u>optionally</u> protected <u>if necessary</u>, with α -hydroxy- γ -butyrolactone wherein any functional group is <u>optionally</u> protected <u>if necessary</u>;

or

(e) the coupling of a quinazoline of the formula VI:

$$A \xrightarrow{R^6} R^5 \xrightarrow{R^4} 0$$

$$O \xrightarrow{R^{5a}} R^{4a} 0$$

$$(R^1)_m$$

VI

wherein R¹, R⁴, R^{4a}, R⁵, R^{5a}, R⁶, A and m have any of the meanings defined in claim 1 except that any functional group is <u>optionally</u> protected <u>if necessary</u>, with a compound of the formula **IIb**:

$$R^{2} \longrightarrow X^{1}-Q^{2}$$

wherein R^2 , R^3 , X^1 , Q^1 and n have any of the meanings defined in claim 1 except that any functional group is <u>optionally</u> protected <u>if necessary</u>;

(f) for the preparation of those compounds of the formula I wherein X¹ is O and Q¹ is 2-pyridyl, 4-pyridyl, 2-pyrimidyl, 2-pyrazinyl or 3-pyridazinyl, the reaction, conveniently in the presence of a suitable base and a suitable catalyst, of a quinazoline of the formula VII:

$$A \longrightarrow \begin{pmatrix} R^6 \\ R^5 \\ N \end{pmatrix}_{m}^{4aO} \begin{pmatrix} R^2 \\ N \end{pmatrix}_{n} \begin{pmatrix} R^3 \\ R^3 \end{pmatrix}_{n}$$

VII

wherein R¹, R², R³, R⁴, R^{4a}, R⁵, R^{5a}, R⁶, A, m and n have any of the meanings defined in claim 1 except that any functional group is <u>optionally</u> protected <u>if necessary</u>, with 2-bromopyridine, 4-bromopyridine, 2-chloropyrimidine, 4-chloropyrimidine, 2-chloropyrizine or 3-chloropyridazine; or

(g) for the preparation of those compounds of the formula I wherein A is Z-($CR^{12}R^{13}$)_p-, wherein Z is $NR^{16}R^{17}$, the reaction, conveniently in the presence of a suitable base, of a quinazoline of the formula **VIII**:

$$L^{1} - (CR^{12}R^{13})_{p} - (R^{5}R^{4}R^{4}R^{2}R^{2}R^{4}R^{2}R^{3})_{n} - (R^{3})_{n}$$

VIII

wherein L¹ is a suitable displaceable group and R¹, R², R³, R⁴, R^{4a}, R⁵, R^{5a}, R⁶, R¹², R¹³, X¹, Q¹, m, n and p have any of the meanings defined in claim 1 except that any functional group is <u>optionally</u> protected <u>if necessary</u>, with a compound of the formula **IXa**, or a reactive derivative thereof:

IXa

wherein R¹⁶ and R¹⁷ have any of the meanings defined in claim 1 except that any functional group is <u>optionally</u> protected <u>if necessary</u>; and thereafter, <u>optionally if necessary</u>:

- (i) converting a quinazoline derivative of the formula I into another quinazoline derivative of the formula I;
- (ii) removing any protecting group that is present by conventional means;
- (iii) forming a pharmaceutically acceptable salt.

Claim 25 (new): A method for treating a tumour sensitive to inhibition of an erbB2 receptor tyrosine kinase in a warm-blooded animal in need of such treatment, which comprises administering to said animal an effective amount of a quinazoline derivative of the formula I, or a pharmaceutically acceptable salt thereof, according to claim 1.

Claim 26 (**new**): The method according to claim 25, wherein the tumour is a solid tumour selected from bile duct, bone, bladder, brain/CNS, breast, colorectal, cervical, endometrial, gastric, head and neck, hepatic, lung, muscle, neuronal, oesophageal, ovarian, pancreatic,

pleural/peritoneal membranes, prostate, renal, skin, testicular, thyroid, uterine and vulval tumours

Claim 27 (**new**): The method according to claim 25, wherein the tumour is a non-solid tumour selected from leukaemia, multiple myeloma and lymphoma.

Claim 28 (**new**): A method for inhibiting an erbB2 receptor tyrosine kinase in a warm-blooded animal in need thereof, which comprises administering to said animal an effective amount of a quinazoline derivative of the formula I, or a pharmaceutically acceptable salt thereof, according to claim 1.

Claim 29 (**new**): A method for selectively inhibiting an erbB2 receptor tyrosine kinase in a warm-blooded animal in need thereof, which comprises administering to said animal an effective amount of a quinazoline derivative of the formula I, or a pharmaceutically acceptable salt thereof, according to claim 1.

Claim 30 (**new**): A method for the production of an anti-proliferative effect in a warm-blooded animal in need thereof, which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase, which method comprises administering to said animal an effective amount of a quinazoline derivative of the formula I, or a pharmaceutically acceptable salt thereof, according to claim 1.